Key result
Diabetes mellitus was independently associated with increased 30-day mortality after transcatheter aortic valve implantation (8.9% vs 3.1%; HR 5.38, 95% CI 1.24-23.25, p=0.024).
Why the study?
Scoring systems to predict survival after TAVI are understudied, and the impact of diabetes and inflammatory conditions remains understudied in this patient group.
Do pre-procedural factors including diabetes, elevated fasting glucose, reduced ejection fraction, and elevated C-reactive protein predict increased all-cause mortality in patients undergoing elective TAVI?
Cohort (n=560)
Do pre-procedural factors including diabetes, elevated fasting glucose, reduced ejection fraction, and elevated C-reactive protein predict increased all-cause mortality in patients undergoing elective TAVI?
Diabetes, elevated fasting glucose, reduced ejection fraction, and elevated CRP are independent predictors of short- and long-term mortality following TAVI, suggesting they should be integrated into pre-procedural risk-assessment tools.
Surgical aortic valve replacement in the elderly is now being supplanted by transcatheter aortic valve implantation (TAVI). Scoring systems to predict survival after catheter-based procedures are understudied. Both diabetes (DM) and underlying inflammatory conditions are common in patients undergoing TAVI, but their impact remains understudied in this patient group. We examined 560 consecutive TAVI procedures and identified eight pre-procedural factors: age, body mass index (BMI), DM, fasting blood glucose (BG), left-ventricular ejection fraction (EF), aortic valve (AV) mean gradient, C-reactive protein levels, and serum creatinine levels and studied their impact on survival. The overall mortality rate at 30 days, 1 year and 2 years were 5.2%, 16.6%, and 34.3%, respectively. All-cause mortality was higher in patients with DM (at 30 days: 8.9% vs. 3.1%, p = 0.008; at 1 year: 19.7% vs. 14.9%, p = 0.323; at 2 years: 37.9% vs. 32.2%, p = 0.304). The presence of DM was independently associated with increased 30-day mortality (hazard ratio [HR] 5.38, 95% confidence interval [CI], 1.24–23.25, p = 0.024). BG levels within 7–11, 1 mmol/L portended an increased risk for 30-day and 2-year mortality compared to normal BG (p = 0.001 and p = 0.027). For each 1 mmol/L increase in BG 30-day mortality increased (HR 1.21, 95% CI, 1.04–1.41, p = 0.015). Reduced EF and elevated CRP were each associated with increased 2-year mortality (p = 0.042 and p = 0.003). DM, elevated BG, reduced EF, and elevated baseline CRP levels each are independent predictors of short- and long-term mortality following TAVI. These easily accessible screening parameters should be integrated into risk-assessment tools for catheter-based aortic valve replacement candidates.
No takes yet. Share an insight, caveat, or question.
Dékány et al. (2022) conducted a cohort in Elective Transcatheter Aortic Valve Implantation (TAVI) (n=560). Diabetes mellitus and elevated fasting blood glucose vs. Absence of diabetes mellitus and normal fasting blood glucose was evaluated on 30-day all-cause mortality (HR 5.38, 95% CI 1.24-23.25, p=0.024). Diabetes mellitus was independently associated with increased 30-day mortality after transcatheter aortic valve implantation (8.9% vs 3.1%; HR 5.38, 95% CI 1.24-23.25, p=0.024).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: